Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the year 2023. For the year 2023, the company expects product revenues, net of $565.0 million to $580.0 million.
Market Closed -
Other stock markets
|
Pre-market 13:12:49 | |||
31.5 USD | -16.80% | 31.96 | +1.46% |
05-10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
05-10 | Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.34% | 1.03B | |
+30.38% | 684B | |
+29.78% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+15.98% | 240B | |
+9.28% | 208B | |
-7.24% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023